{"ticker": {"uuid": "471f2a5d-792e-49b6-b35f-2750ab7f4d60", "symbol": "ATHE", "name": "Alterity Therapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that its CEO, Dr. David Stamler, will participate in the virtual BTIG Biotechnology Conference 2026 from July 28-29, 2026. Dr. Stamler will conduct one-on-one meetings with investors to discuss the company's progress in dev", "url": "https://sg.finance.yahoo.com/news/alterity-therapeutics-participate-virtual-btig-112500348.html", "source_name": "Market source", "published_at": "2026-07-21T11:09:47", "published_display": "21 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity CEO to Host 1-on-1 U.S. Investor Meetings", "summary": "Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. Dr. Stamler will host one-on-one meetings with U.S. investors to discuss the company's progre", "url": "https://www.stocktitan.net/news/ATHE/alterity-therapeutics-to-participate-in-the-virtual-btig-y54yg4iy42y1.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:09:47", "published_display": "21 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech event", "summary": "Alterity Therapeutics will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. CEO David Stamler, M.D., will host one-on-one meetings with investors to discuss the company's focus on disease-modifying therapies for neurodegenerative diseases, partic", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-5591c68284d9.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:09:47", "published_display": "21 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)", "summary": "ALTERITY THERAPEUTICS LTD filed a Form 6-K Current Report with the SEC on July 21, 2026. This foreign private issuer report indicates the company's compliance with SEC regulations and is incorporated by reference into several of its registration statements. The report includes an", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-cd84b204e1e1.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:09:47", "published_display": "21 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd Warrant 2023 - 31.08.26 On Alterity Financial Disclosures & Filings", "summary": "This article provides access to financial disclosures and filings for Alterity Therapeutics Ltd (ATHo) Warrant 2023 - 31.08.26. It lists various corporate documents, including earnings reports, corporate presentations, and study updates from 2023 to 2026, highlighting the develop", "url": "https://www.tradingview.com/symbols/ASX-ATHO/documents/", "source_name": "TradingView", "published_at": "2026-07-21T09:09:47", "published_display": "21 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics CEO to Present at Virtual BTIG Biotechnology Conference 2026", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a clinical-stage biotechnology company, announced that CEO Dr. David Stamler will present at the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. The company will conduct one-on-one investor meetings to discuss its le", "url": "https://kalkine.com.au/news/announcements/alterity-therapeutics-ceo-to-present-at-virtual-btig-biotechnology-conference-2026", "source_name": "Kalkine", "published_at": "2026-07-21T07:09:47", "published_display": "21 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics CEO to Speak at Virtual BTIG Biotechnology Conference 2026 on July 28-29", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a clinical-stage biotechnology company, announced that CEO Dr. David Stamler will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29. The company plans to hold one-on-one investor meetings at the conference ", "url": "https://kalkinemedia.com/au/news/announcements/alterity-therapeutics-ceo-to-speak-at-virtual-btig-biotechnology-conference-2026-on-july-28-29", "source_name": "Kalkine Media", "published_at": "2026-07-21T07:09:47", "published_display": "21 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Converts 40,209 Options Into Ordinary Shares at 50 Cents Each", "summary": "Alterity Therapeutics (ASX: ATH) has converted 40,209 options into ordinary fully paid shares at an exercise price of AUD 0.50 per share, generating AUD 20,104.50. This conversion increases the company's quoted ordinary share capital to 217,629,367 shares. The company maintains a", "url": "https://kalkine.com.au/news/announcements/alterity-therapeutics-converts-40209-options-into-ordinary-shares-at-50-cents-each", "source_name": "Kalkine", "published_at": "2026-07-21T03:03:13", "published_display": "21 Jul 2026 03:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Executes Conversion of 40,209 Options into Ordinary Shares at AUD 0.50 Each", "summary": "Alterity Therapeutics (ATH) has converted 40,209 options into ordinary fully paid shares, issued at AUD 0.50 each on July 21, 2026. This conversion increases the company's total quoted ordinary share capital to 217,629,367 shares. The company still retains a significant number of", "url": "https://kalkinemedia.com/au/news/announcements/alterity-therapeutics-executes-conversion-of-40209-options-into-ordinary-shares-at-aud-050-each", "source_name": "Kalkine Media", "published_at": "2026-07-21T03:03:13", "published_display": "21 Jul 2026 03:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains Alterity Therapeutics(ATHE.US) With Buy Rating, Maintains Target Price $16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRTJldDZ1MVQ3eUtwdHI0a3pLOFBVZzJwRFN1ZTlFLVFha0RidUhTTHlYdVNCVGhTeHR4VTZMNEE1TXh2MUZvZFFfczJWTVlqVldhWmxXdkJoMTVPS3hLUWtQbm9wXzBqNVMyXzVQdEtQOUlPNlNvaDFUR3ZQNGNwREJ6aUtwQW5ZMU5QMGZXMExMZi0wTzRSYm51bFRLQWo3MXNIMko0Nk5ObDR6RGR0UXhRX3NJMVlHQ0V4U29VRWRGQ1E?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-20T00:00:10+00:00", "published_display": "20 Jul 2026 00:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alterity Therapeutics (ASX:ATH) Declines Nearly 9.5% \u2014 What Is Behind the Neurodegeneration Drug Developer\u2019s Fall?", "summary": "Alterity Therapeutics (ASX:ATH) experienced a nearly 9.5% decline in its share price. The company is a neurodegeneration drug developer, and its stock performance is closely linked to clinical trial outcomes and broader sector sentiment. Investors are advised to monitor the compa", "url": "https://kalkine.com.au/news/healthcare/alterity-therapeutics-asxath-declines-nearly-95-what-is-behind-the-neurodegeneration-drug-developers-fall", "source_name": "Kalkine", "published_at": "2026-07-14T05:41:10", "published_display": "14 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX", "summary": "Alterity Therapeutics (ASX:ATH), a clinical-stage biotechnology company focused on neurodegenerative diseases, saw its share price fall, highlighting the inherent volatility of such stocks. The company is developing ATH434 for Multiple System Atrophy and has reported positive reg", "url": "https://kalkine.com.au/news/general-news/alterity-therapeutics-asxath-falls-as-biotech-volatility-returns-to-the-asx", "source_name": "Kalkine", "published_at": "2026-07-10T13:09:34", "published_display": "10 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received an AU$4 million cash refund under the Australian government's R&D tax incentive program. This refund is related to eligible research and development expenditures incurred during the 2023-2024 financial year. The funds wi", "url": "https://www.moomoo.com/news/post/72691098/alterity-therapeutics-receives-au-4-million-tax-refund-from-australian", "source_name": "Moomoo", "published_at": "2026-07-09T11:17:06", "published_display": "09 Jul 2026 11:17", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K", "summary": "Alterity Therapeutics Limited (ATHE) filed a Form 6-K Current Report with the SEC on July 9, 2026, confirming its status as a foreign private issuer. This filing indicates that the company will continue to file annual reports under Form 20-F and confirms the incorporation by refe", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-2d8817216d8a.html", "source_name": "Stock Titan", "published_at": "2026-07-09T11:09:50", "published_display": "09 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (NASDAQ: ATHE) receives A$3.98m R&D tax refund", "summary": "Alterity Therapeutics has received an A$3.98 million R&D tax refund for the 2025 financial year from the Australian Government, including interest. This non-dilutive funding will support the company's ongoing clinical programs, particularly the development of its lead candidate A", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-2875899fccd9.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:09:50", "published_display": "09 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Announces Quotation of New Securities Following Option Conversion", "summary": "Alterity Therapeutics (ASX: ATH) has announced the quotation of 76,191 new ordinary fully paid shares on the ASX following the conversion of options with an issue price of AUD 0.50 per share. This strategic move increases the company's total shares to 217,589,158 and aims to enha", "url": "https://kalkine.com.au/news/announcements/alterity-therapeutics-announces-quotation-of-new-securities-following-option-conversion", "source_name": "Kalkine", "published_at": "2026-07-09T02:09:50", "published_display": "09 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathway", "summary": "Alterity Therapeutics has secured FDA confirmation for a registrational pathway for its lead drug candidate, ATH434, for Multiple System Atrophy (MSA). The FDA agreed to a single pivotal Phase 3 trial supported by confirmatory evidence, clarifying the clinical development strateg", "url": "https://www.proactiveinvestors.com/companies/news/1095013/alterity-therapeutics-clears-key-fda-hurdle-for-ath434-phase-3-pathway-1095013.html", "source_name": "Proactive financial news", "published_at": "2026-07-08T00:11:14", "published_display": "08 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy", "summary": "Alterity Therapeutics announced that the FDA has endorsed its Phase 3 clinical trial design for ATH434, a treatment for Multiple System Atrophy (MSA). This agreement marks a significant step forward for the therapy which aims to address the neurodegenerative disorder. The FDA's s", "url": "https://www.moomoo.com/news/post/72584347/alterity-therapeutics-says-fda-backs-phase-3-design-for-multiple", "source_name": "Moomoo", "published_at": "2026-07-07T14:40:00", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics aligns with FDA on Phase 3 neurology drug path", "summary": "Alterity Therapeutics has received official FDA meeting minutes, confirming the regulatory pathway for its ATH434 Phase 3 Multiple System Atrophy drug trial. The FDA has agreed that a single pivotal efficacy study, supported by existing Phase 2 findings, will be sufficient for a ", "url": "https://grafa.com/en/news/united-states/alterity-therapeutics-fda-alignment-ath434-phase3", "source_name": "grafa.com", "published_at": "2026-07-07T14:14:00", "published_display": "07 Jul 2026 14:14", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (ATHE) Advances Towards Phase 3 Trial Appr", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRGM2cmRBdTRqQW1SWVYyQjBuQTd3QVNPOGpESjRwSXdBTzlDRXRqNEU3TVNfLWM5d2phVFdVekV0WldMVGlzQk03NktDTS1xUFBzckx6eHdwbXlKRkpvbnU0ZUhIY3A0LUJ6cFF4S0JxcDJON1pKY01TR0daSjlJbGtVcVFEeld2NW55cTU1U0hlbGR2TFgxUmZNLWVxYXNWMXNwaHJxZVI?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-07T12:06:37+00:00", "published_display": "07 Jul 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alterity-therapeutics-receives-fda-end-110500645.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:05:00+00:00", "published_display": "07 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs single Phase 3 trial for Alterity\u2019s MSA drug ATH434", "summary": "Alterity Therapeutics has received official FDA End-of-Phase 2 meeting minutes for its drug ATH434, confirming a clear registrational pathway for Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, along with existing Phase 2 data as confirmatory ev", "url": "https://www.stocktitan.net/news/ATHE/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-nrbub39j2f8o.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:05:18", "published_display": "07 Jul 2026 11:05", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA outlines single Phase 3 trial plan for Alterity (NASDAQ: ATHE) ATH434", "summary": "Alterity Therapeutics announced that the FDA has confirmed a single pivotal Phase 3 trial, supported by confirmatory evidence, is sufficient for potential approval of ATH434 for Multiple System Atrophy (MSA). The Phase 3 study, expected to enroll approximately 200 patients, will ", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-baf43259adef.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:10:19", "published_display": "07 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4%", "summary": "Alterity Therapeutics announced that minutes from its recent meeting with the U.S. FDA confirmed the key elements of its Phase 3 clinical program for ATH434, a treatment candidate for Multiple System Atrophy (MSA). The FDA agreed on the primary endpoint, patient population, and s", "url": "https://www.moomoo.com/news/post/72553236/alterity-therapeutics-says-us-fda-meeting-minutes-confirm-key-elements?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T02:39:17", "published_display": "06 Jul 2026 02:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd Warrant 2025-26.02.27 on Alterity Thera Financial Disclosures & Filings", "summary": "This article provides a list of financial disclosures and filings for Alterity Therapeutics Ltd Warrant 2025-26.02.27 (ATHOA) on the Australian Securities Exchange. The documents span from 2023 to 2026, primarily focusing on earnings reports, corporate presentations, and study up", "url": "https://www.tradingview.com/symbols/ASX-ATHOA/documents/", "source_name": "TradingView", "published_at": "2026-07-01T22:10:40", "published_display": "01 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Alterity Therapeutics Ltd. \u2013 ASX:ATH", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Alterity Therapeutics Ltd. (ASX:ATH). It indicates that the market regarding this particular financial data is currently closed with no trades. The content is primarily a data placeholder within a financi", "url": "https://www.tradingview.com/symbols/ASX-ATH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:39:45", "published_display": "27 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd (ATH) News Flow", "summary": "This article states that it provides a news flow for Alterity Therapeutics Ltd (ATH). However, the content provided is just the word \"Document,\" indicating that the actual news flow information is missing or not provided in the input.", "url": "https://www.moomoo.com/stock/ATH-AU/news?chain_id=Name1K9-3FXPhg.1ku09k0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2Fspyxapyl-8112-104269302%2Fpost%2Fall%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T21:40:58", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Alterity Therapeutics Ltd Warrant 2023-31.08.26, traded on the ASX under the ticker ATHDB. It provides an overview for potential investors examining the financial aspects of this specific warrant. The ar", "url": "https://www.tradingview.com/symbols/ASX-ATHDB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:20", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alteriry Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ATHE)", "summary": "This article provides access to the financial actuals and estimates for Alterity Therapeutics Limited (NASDAQ: ATHE) via TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform e", "url": "https://www.tradingview.com/symbols/NASDAQ-ATHE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:39:20", "published_display": "26 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity in earnings of Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery \u2013 ASX:ATHDB", "summary": "This article displays the \"Equity in earnings\" section for Alterity Therapeutics Ltd Warrant 2023-31.08.26, traded on the Australian Securities Exchange under the ticker ATHDB. It provides a financial overview, though no specific data is presented in the provided content as the m", "url": "https://www.tradingview.com/symbols/ASX-ATHDB/financials-income-statement/equity-in-earnings/", "source_name": "TradingView", "published_at": "2026-06-26T05:11:57", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Alterity (NASDAQ: ATHE) receives 2M options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUl9nVWJKVFkxaXRjb1huNWJuejdleTJiQ1JuQkg1MGlJNS1lYXMwbUpzWFhGOXlfaDhqVVVvR3BxR2pWZFB2Z203Y0NBdmxLdWZ4blFvZTJUYTdzSF9HUUpqQmRicENvekN3RXQ2cDFCV192MUlreThlc0pNOHFBajRWNmZPVDJURFdDMTNmbmZDU2VMT3ViVTdnUzJJZ2lGMVVtRXQzZXVGR2VmUU1tcVRDMlh3eVNSNm5r?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdDB6WHdBcHhmNnRBbjNWZkRLY1hUUnRfUzFEOXk0OWJZOEZuUGF6ZlpVTGZ4Zk5tUkhNSnJMZF9xTHM3aEVOLW1ubjBkT2hZd0xSWEtEZ2hUNGgtTGFLNzExLTBrTzQ0d2ptaERvX1N3ajYyckhpMUI4amdWNWFZeV82aXI1ZEx4MTV4S3hLNEExQXhvYWlXVms3ZXU4RDN4UUFyM3JyckJwX1Izamc?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX: ATH \u2014 Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPN2UzRlVaUzNaS3N4VkVycnVmSHZ3X2NMSUNQbl9xSVhyUUdMdWs5R1kzWklwTzI3MUtTeHVISzRBVXRBVlNCNlQzaHVqMmZYdWtRemNNTkZXNGt3RVJkMTUzV2N3Z2RwR1RRYjdJVDVGODYwTFVMS09JWlNvMFlYMTMxTWlvV0dnb3VoZEZ5bXhlUW85LW9MdUFtMmdZTThvY2ZEcjhOem9Mb2NNTERiZk92N3lLUUs2?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOQVNpMDBFS2pRY0JscGtybUhFOTVYNUlHajl3MmcyemUyWHBGRm1ITlFTb3d3UlFYcjNRS1R0MFNoUnBJVjJiQmNoT0RYYmFmbUZMTXBnSEJvWVg2dGE2X3JpZmpFaTJGdWNmdjROdGlCc2NlcnlVeHh4UUpka2ZXMmpxWGFzYzFQa3l1RDBGOXhWVW5qZ1p0LVFGTVVjdWpJaXMtNHBDaFRUWktVX3VhYg?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNQTg4M1BBcFZOMEEwbTBDS21LLUEzc1Q5aTdFeUNjUElNc3dfWDhtanNMVE1qck5UaFR6VUdsQ2FVUDJvM3pxRnowb1JsZFV6c19POUJwYUdEdlhDS2NlUW9kVllZeElMZExaYlZjZ2U3U2NpZmxsaHBfZ2tLYWtjMURPc01CN09IeFFOZExqek55REc3MXUzMlU3SkI5VU1vTUhWX1E1dXlfOFl3RGJsSFhFcXpKOFJpdWZLVmVQVzJBTzFTRmc2bXJhci1VWHBo?oc=5", "source_name": "Kalkine", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-data-presentations-support-112500492.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:25:00+00:00", "published_display": "19 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-announces-publication-demonstrating-112500299.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:25:00+00:00", "published_display": "11 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-deliver-presentations-multiple-112500532.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T11:25:00+00:00", "published_display": "07 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Releases Appendix 4C \u2013 Q3 FY26 Quarterly Cash Flow Report & Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-releases-appendix-4c-112500612.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T11:25:00+00:00", "published_display": "30 Apr 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity says FDA supported key Phase 3 steps for MSA drug ATH434", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPX0hib1ZEVlhZRzBaRzdrM3A2WFd2ZDlIN1dkUEVPU3JNQVJseDFZb0h3bzhwbjNXN25SUVhXaHZjZWFHZExpVjRQRzU2aGVmSjFQZ09Zc3d4LVJiOFhJSVN5UDdQdlJmdFNYWm0xOHJVYWktM3RjZFBLM3MzOU4wUXRmMHp2QjJhSXBPbnlwRE5QTDhFek9ldUxvS0ZtdUluSzNWaDZ1VEdrd054M0d2SkZqb1VsbndlUnN2TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that its CEO, Dr. David Stamler, will participate in the virtual BTIG Biotechnology Conference 2026 from July 28-29, 2026. Dr. Stamler will conduct one-on-one meetings with investors to discuss the company's progress in dev", "url": "https://sg.finance.yahoo.com/news/alterity-therapeutics-participate-virtual-btig-112500348.html", "source_name": "Market source", "published_at": "2026-07-21T11:09:47", "published_display": "21 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity CEO to Host 1-on-1 U.S. Investor Meetings", "summary": "Alterity Therapeutics (NASDAQ: ATHE, ASX: ATH) announced that CEO David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. Dr. Stamler will host one-on-one meetings with U.S. investors to discuss the company's progre", "url": "https://www.stocktitan.net/news/ATHE/alterity-therapeutics-to-participate-in-the-virtual-btig-y54yg4iy42y1.html", "source_name": "Stock Titan", "published_at": "2026-07-21T11:09:47", "published_display": "21 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech event", "summary": "Alterity Therapeutics will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. CEO David Stamler, M.D., will host one-on-one meetings with investors to discuss the company's focus on disease-modifying therapies for neurodegenerative diseases, partic", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-5591c68284d9.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:09:47", "published_display": "21 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer)", "summary": "ALTERITY THERAPEUTICS LTD filed a Form 6-K Current Report with the SEC on July 21, 2026. This foreign private issuer report indicates the company's compliance with SEC regulations and is incorporated by reference into several of its registration statements. The report includes an", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-cd84b204e1e1.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:09:47", "published_display": "21 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd Warrant 2023 - 31.08.26 On Alterity Financial Disclosures & Filings", "summary": "This article provides access to financial disclosures and filings for Alterity Therapeutics Ltd (ATHo) Warrant 2023 - 31.08.26. It lists various corporate documents, including earnings reports, corporate presentations, and study updates from 2023 to 2026, highlighting the develop", "url": "https://www.tradingview.com/symbols/ASX-ATHO/documents/", "source_name": "TradingView", "published_at": "2026-07-21T09:09:47", "published_display": "21 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics CEO to Present at Virtual BTIG Biotechnology Conference 2026", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a clinical-stage biotechnology company, announced that CEO Dr. David Stamler will present at the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. The company will conduct one-on-one investor meetings to discuss its le", "url": "https://kalkine.com.au/news/announcements/alterity-therapeutics-ceo-to-present-at-virtual-btig-biotechnology-conference-2026", "source_name": "Kalkine", "published_at": "2026-07-21T07:09:47", "published_display": "21 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics CEO to Speak at Virtual BTIG Biotechnology Conference 2026 on July 28-29", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a clinical-stage biotechnology company, announced that CEO Dr. David Stamler will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29. The company plans to hold one-on-one investor meetings at the conference ", "url": "https://kalkinemedia.com/au/news/announcements/alterity-therapeutics-ceo-to-speak-at-virtual-btig-biotechnology-conference-2026-on-july-28-29", "source_name": "Kalkine Media", "published_at": "2026-07-21T07:09:47", "published_display": "21 Jul 2026 07:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Converts 40,209 Options Into Ordinary Shares at 50 Cents Each", "summary": "Alterity Therapeutics (ASX: ATH) has converted 40,209 options into ordinary fully paid shares at an exercise price of AUD 0.50 per share, generating AUD 20,104.50. This conversion increases the company's quoted ordinary share capital to 217,629,367 shares. The company maintains a", "url": "https://kalkine.com.au/news/announcements/alterity-therapeutics-converts-40209-options-into-ordinary-shares-at-50-cents-each", "source_name": "Kalkine", "published_at": "2026-07-21T03:03:13", "published_display": "21 Jul 2026 03:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Executes Conversion of 40,209 Options into Ordinary Shares at AUD 0.50 Each", "summary": "Alterity Therapeutics (ATH) has converted 40,209 options into ordinary fully paid shares, issued at AUD 0.50 each on July 21, 2026. This conversion increases the company's total quoted ordinary share capital to 217,629,367 shares. The company still retains a significant number of", "url": "https://kalkinemedia.com/au/news/announcements/alterity-therapeutics-executes-conversion-of-40209-options-into-ordinary-shares-at-aud-050-each", "source_name": "Kalkine Media", "published_at": "2026-07-21T03:03:13", "published_display": "21 Jul 2026 03:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JonesTrading Maintains Alterity Therapeutics(ATHE.US) With Buy Rating, Maintains Target Price $16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRTJldDZ1MVQ3eUtwdHI0a3pLOFBVZzJwRFN1ZTlFLVFha0RidUhTTHlYdVNCVGhTeHR4VTZMNEE1TXh2MUZvZFFfczJWTVlqVldhWmxXdkJoMTVPS3hLUWtQbm9wXzBqNVMyXzVQdEtQOUlPNlNvaDFUR3ZQNGNwREJ6aUtwQW5ZMU5QMGZXMExMZi0wTzRSYm51bFRLQWo3MXNIMko0Nk5ObDR6RGR0UXhRX3NJMVlHQ0V4U29VRWRGQ1E?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-20T00:00:10+00:00", "published_display": "20 Jul 2026 00:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (ASX:ATH) Declines Nearly 9.5% \u2014 What Is Behind the Neurodegeneration Drug Developer\u2019s Fall?", "summary": "Alterity Therapeutics (ASX:ATH) experienced a nearly 9.5% decline in its share price. The company is a neurodegeneration drug developer, and its stock performance is closely linked to clinical trial outcomes and broader sector sentiment. Investors are advised to monitor the compa", "url": "https://kalkine.com.au/news/healthcare/alterity-therapeutics-asxath-declines-nearly-95-what-is-behind-the-neurodegeneration-drug-developers-fall", "source_name": "Kalkine", "published_at": "2026-07-14T05:41:10", "published_display": "14 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (ASX:ATH) Falls as Biotech Volatility Returns to the ASX", "summary": "Alterity Therapeutics (ASX:ATH), a clinical-stage biotechnology company focused on neurodegenerative diseases, saw its share price fall, highlighting the inherent volatility of such stocks. The company is developing ATH434 for Multiple System Atrophy and has reported positive reg", "url": "https://kalkine.com.au/news/general-news/alterity-therapeutics-asxath-falls-as-biotech-volatility-returns-to-the-asx", "source_name": "Kalkine", "published_at": "2026-07-10T13:09:34", "published_display": "10 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Receives AU$4 Million Tax Refund From Australian Government", "summary": "Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has received an AU$4 million cash refund under the Australian government's R&D tax incentive program. This refund is related to eligible research and development expenditures incurred during the 2023-2024 financial year. The funds wi", "url": "https://www.moomoo.com/news/post/72691098/alterity-therapeutics-receives-au-4-million-tax-refund-from-australian", "source_name": "Moomoo", "published_at": "2026-07-09T11:17:06", "published_display": "09 Jul 2026 11:17", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC Filing - Form 6-K", "summary": "Alterity Therapeutics Limited (ATHE) filed a Form 6-K Current Report with the SEC on July 9, 2026, confirming its status as a foreign private issuer. This filing indicates that the company will continue to file annual reports under Form 20-F and confirms the incorporation by refe", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-2d8817216d8a.html", "source_name": "Stock Titan", "published_at": "2026-07-09T11:09:50", "published_display": "09 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (NASDAQ: ATHE) receives A$3.98m R&D tax refund", "summary": "Alterity Therapeutics has received an A$3.98 million R&D tax refund for the 2025 financial year from the Australian Government, including interest. This non-dilutive funding will support the company's ongoing clinical programs, particularly the development of its lead candidate A", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-2875899fccd9.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:09:50", "published_display": "09 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Announces Quotation of New Securities Following Option Conversion", "summary": "Alterity Therapeutics (ASX: ATH) has announced the quotation of 76,191 new ordinary fully paid shares on the ASX following the conversion of options with an issue price of AUD 0.50 per share. This strategic move increases the company's total shares to 217,589,158 and aims to enha", "url": "https://kalkine.com.au/news/announcements/alterity-therapeutics-announces-quotation-of-new-securities-following-option-conversion", "source_name": "Kalkine", "published_at": "2026-07-09T02:09:50", "published_display": "09 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathway", "summary": "Alterity Therapeutics has secured FDA confirmation for a registrational pathway for its lead drug candidate, ATH434, for Multiple System Atrophy (MSA). The FDA agreed to a single pivotal Phase 3 trial supported by confirmatory evidence, clarifying the clinical development strateg", "url": "https://www.proactiveinvestors.com/companies/news/1095013/alterity-therapeutics-clears-key-fda-hurdle-for-ath434-phase-3-pathway-1095013.html", "source_name": "Proactive financial news", "published_at": "2026-07-08T00:11:14", "published_display": "08 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Says FDA Backs Phase 3 Design for Multiple System Atrophy Therapy", "summary": "Alterity Therapeutics announced that the FDA has endorsed its Phase 3 clinical trial design for ATH434, a treatment for Multiple System Atrophy (MSA). This agreement marks a significant step forward for the therapy which aims to address the neurodegenerative disorder. The FDA's s", "url": "https://www.moomoo.com/news/post/72584347/alterity-therapeutics-says-fda-backs-phase-3-design-for-multiple", "source_name": "Moomoo", "published_at": "2026-07-07T14:40:00", "published_display": "07 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics aligns with FDA on Phase 3 neurology drug path", "summary": "Alterity Therapeutics has received official FDA meeting minutes, confirming the regulatory pathway for its ATH434 Phase 3 Multiple System Atrophy drug trial. The FDA has agreed that a single pivotal efficacy study, supported by existing Phase 2 findings, will be sufficient for a ", "url": "https://grafa.com/en/news/united-states/alterity-therapeutics-fda-alignment-ath434-phase3", "source_name": "grafa.com", "published_at": "2026-07-07T14:14:00", "published_display": "07 Jul 2026 14:14", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (ATHE) Advances Towards Phase 3 Trial Appr", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRGM2cmRBdTRqQW1SWVYyQjBuQTd3QVNPOGpESjRwSXdBTzlDRXRqNEU3TVNfLWM5d2phVFdVekV0WldMVGlzQk03NktDTS1xUFBzckx6eHdwbXlKRkpvbnU0ZUhIY3A0LUJ6cFF4S0JxcDJON1pKY01TR0daSjlJbGtVcVFEeld2NW55cTU1U0hlbGR2TFgxUmZNLWVxYXNWMXNwaHJxZVI?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-07T12:06:37+00:00", "published_display": "07 Jul 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alterity-therapeutics-receives-fda-end-110500645.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:05:00+00:00", "published_display": "07 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs single Phase 3 trial for Alterity\u2019s MSA drug ATH434", "summary": "Alterity Therapeutics has received official FDA End-of-Phase 2 meeting minutes for its drug ATH434, confirming a clear registrational pathway for Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, along with existing Phase 2 data as confirmatory ev", "url": "https://www.stocktitan.net/news/ATHE/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-nrbub39j2f8o.html", "source_name": "Stock Titan", "published_at": "2026-07-07T11:05:18", "published_display": "07 Jul 2026 11:05", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA outlines single Phase 3 trial plan for Alterity (NASDAQ: ATHE) ATH434", "summary": "Alterity Therapeutics announced that the FDA has confirmed a single pivotal Phase 3 trial, supported by confirmatory evidence, is sufficient for potential approval of ATH434 for Multiple System Atrophy (MSA). The Phase 3 study, expected to enroll approximately 200 patients, will ", "url": "https://www.stocktitan.net/sec-filings/ATHE/6-k-alterity-therapeutics-ltd-current-report-foreign-issuer-baf43259adef.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:10:19", "published_display": "07 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Says US FDA Meeting Minutes Confirm Key Elements of Phase 3 MSA Treatment Candidate Program; Shares Fall 4%", "summary": "Alterity Therapeutics announced that minutes from its recent meeting with the U.S. FDA confirmed the key elements of its Phase 3 clinical program for ATH434, a treatment candidate for Multiple System Atrophy (MSA). The FDA agreed on the primary endpoint, patient population, and s", "url": "https://www.moomoo.com/news/post/72553236/alterity-therapeutics-says-us-fda-meeting-minutes-confirm-key-elements?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T02:39:17", "published_display": "06 Jul 2026 02:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd Warrant 2025-26.02.27 on Alterity Thera Financial Disclosures & Filings", "summary": "This article provides a list of financial disclosures and filings for Alterity Therapeutics Ltd Warrant 2025-26.02.27 (ATHOA) on the Australian Securities Exchange. The documents span from 2023 to 2026, primarily focusing on earnings reports, corporate presentations, and study up", "url": "https://www.tradingview.com/symbols/ASX-ATHOA/documents/", "source_name": "TradingView", "published_at": "2026-07-01T22:10:40", "published_display": "01 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Alterity Therapeutics Ltd. \u2013 ASX:ATH", "summary": "The article focuses on the \"Price to earnings forward\" financial metric for Alterity Therapeutics Ltd. (ASX:ATH). It indicates that the market regarding this particular financial data is currently closed with no trades. The content is primarily a data placeholder within a financi", "url": "https://www.tradingview.com/symbols/ASX-ATH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:39:45", "published_display": "27 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd (ATH) News Flow", "summary": "This article states that it provides a news flow for Alterity Therapeutics Ltd (ATH). However, the content provided is just the word \"Document,\" indicating that the actual news flow information is missing or not provided in the input.", "url": "https://www.moomoo.com/stock/ATH-AU/news?chain_id=Name1K9-3FXPhg.1ku09k0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A64,%22f%22%3A%22www.moomoo.com%2Fcommunity%2Fprofile%2Fspyxapyl-8112-104269302%2Fpost%2Fall%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T21:40:58", "published_display": "26 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Alterity Therapeutics Ltd Warrant 2023-31.08.26, traded on the ASX under the ticker ATHDB. It provides an overview for potential investors examining the financial aspects of this specific warrant. The ar", "url": "https://www.tradingview.com/symbols/ASX-ATHDB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:20", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alteriry Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:ATHE)", "summary": "This article provides access to the financial actuals and estimates for Alterity Therapeutics Limited (NASDAQ: ATHE) via TradingView. It allows users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform e", "url": "https://www.tradingview.com/symbols/NASDAQ-ATHE/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:39:20", "published_display": "26 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity in earnings of Alterity Therapeutics Ltd Warrant 2023-31.08.26 on Alterity/Deferred Delivery \u2013 ASX:ATHDB", "summary": "This article displays the \"Equity in earnings\" section for Alterity Therapeutics Ltd Warrant 2023-31.08.26, traded on the Australian Securities Exchange under the ticker ATHDB. It provides a financial overview, though no specific data is presented in the provided content as the m", "url": "https://www.tradingview.com/symbols/ASX-ATHDB/financials-income-statement/equity-in-earnings/", "source_name": "TradingView", "published_at": "2026-06-26T05:11:57", "published_display": "26 Jun 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Alterity (NASDAQ: ATHE) receives 2M options grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUl9nVWJKVFkxaXRjb1huNWJuejdleTJiQ1JuQkg1MGlJNS1lYXMwbUpzWFhGOXlfaDhqVVVvR3BxR2pWZFB2Z203Y0NBdmxLdWZ4blFvZTJUYTdzSF9HUUpqQmRicENvekN3RXQ2cDFCV192MUlreThlc0pNOHFBajRWNmZPVDJURFdDMTNmbmZDU2VMT3ViVTdnUzJJZ2lGMVVtRXQzZXVGR2VmUU1tcVRDMlh3eVNSNm5r?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdDB6WHdBcHhmNnRBbjNWZkRLY1hUUnRfUzFEOXk0OWJZOEZuUGF6ZlpVTGZ4Zk5tUkhNSnJMZF9xTHM3aEVOLW1ubjBkT2hZd0xSWEtEZ2hUNGgtTGFLNzExLTBrTzQ0d2ptaERvX1N3ajYyckhpMUI4amdWNWFZeV82aXI1ZEx4MTV4S3hLNEExQXhvYWlXVms3ZXU4RDN4UUFyM3JyckJwX1Izamc?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX: ATH \u2014 Alterity Therapeutics Wins Key FDA Alignment as Neuro Trial Hopes Rise", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPN2UzRlVaUzNaS3N4VkVycnVmSHZ3X2NMSUNQbl9xSVhyUUdMdWs5R1kzWklwTzI3MUtTeHVISzRBVXRBVlNCNlQzaHVqMmZYdWtRemNNTkZXNGt3RVJkMTUzV2N3Z2RwR1RRYjdJVDVGODYwTFVMS09JWlNvMFlYMTMxTWlvV0dnb3VoZEZ5bXhlUW85LW9MdUFtMmdZTThvY2ZEcjhOem9Mb2NNTERiZk92N3lLUUs2?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOQVNpMDBFS2pRY0JscGtybUhFOTVYNUlHajl3MmcyemUyWHBGRm1ITlFTb3d3UlFYcjNRS1R0MFNoUnBJVjJiQmNoT0RYYmFmbUZMTXBnSEJvWVg2dGE2X3JpZmpFaTJGdWNmdjROdGlCc2NlcnlVeHh4UUpka2ZXMmpxWGFzYzFQa3l1RDBGOXhWVW5qZ1p0LVFGTVVjdWpJaXMtNHBDaFRUWktVX3VhYg?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics (ASX:ATH) Stock in Focus After FDA Endorses Registrational Pathway for ATH434", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNQTg4M1BBcFZOMEEwbTBDS21LLUEzc1Q5aTdFeUNjUElNc3dfWDhtanNMVE1qck5UaFR6VUdsQ2FVUDJvM3pxRnowb1JsZFV6c19POUJwYUdEdlhDS2NlUW9kVllZeElMZExaYlZjZ2U3U2NpZmxsaHBfZ2tLYWtjMURPc01CN09IeFFOZExqek55REc3MXUzMlU3SkI5VU1vTUhWX1E1dXlfOFl3RGJsSFhFcXpKOFJpdWZLVmVQVzJBTzFTRmc2bXJhci1VWHBo?oc=5", "source_name": "Kalkine", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-data-presentations-support-112500492.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T11:25:00+00:00", "published_display": "19 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-announces-publication-demonstrating-112500299.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:25:00+00:00", "published_display": "11 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-deliver-presentations-multiple-112500532.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T11:25:00+00:00", "published_display": "07 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity Therapeutics Releases Appendix 4C \u2013 Q3 FY26 Quarterly Cash Flow Report & Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alterity-therapeutics-releases-appendix-4c-112500612.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T11:25:00+00:00", "published_display": "30 Apr 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alterity says FDA supported key Phase 3 steps for MSA drug ATH434", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPX0hib1ZEVlhZRzBaRzdrM3A2WFd2ZDlIN1dkUEVPU3JNQVJseDFZb0h3bzhwbjNXN25SUVhXaHZjZWFHZExpVjRQRzU2aGVmSjFQZ09Zc3d4LVJiOFhJSVN5UDdQdlJmdFNYWm0xOHJVYWktM3RjZFBLM3MzOU4wUXRmMHp2QjJhSXBPbnlwRE5QTDhFek9ldUxvS0ZtdUluSzNWaDZ1VEdrd054M0d2SkZqb1VsbndlUnN2TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 49, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 33, "score": 57, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.98, "latest_week": "2026-07-17", "one_week_move": -8.3, "four_week_move": 2.0, "twelve_week_move": 12.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.148921, "market_dynamics_buy_signal": false, "relative_strength": 7.75457, "fair_value_gap": 61.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 45.2569, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.3% over one week, +2.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "Kalkine", "count": 7}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Kalkine Media", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-8.3% over one week, +2.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026"}], "updated_at": "2026-07-22T22:55:37.406687+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}